Johnson & Johnson EPS - Earnings per Share 2010-2024 | JNJ
Johnson & Johnson annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Johnson & Johnson EPS for the quarter ending September 30, 2024 was $1.11, a 89.13% decline year-over-year.
- Johnson & Johnson EPS for the twelve months ending September 30, 2024 was $5.96, a 55.72% decline year-over-year.
- Johnson & Johnson 2023 annual EPS was $13.72, a 103.86% increase from 2022.
- Johnson & Johnson 2022 annual EPS was $6.73, a 13.83% decline from 2021.
- Johnson & Johnson 2021 annual EPS was $7.81, a 41.74% increase from 2020.
| Johnson & Johnson Annual EPS |
| 2023 |
$13.72 |
| 2022 |
$6.73 |
| 2021 |
$7.81 |
| 2020 |
$5.51 |
| 2019 |
$5.63 |
| 2018 |
$5.61 |
| 2017 |
$0.47 |
| 2016 |
$5.93 |
| 2015 |
$5.48 |
| 2014 |
$5.70 |
| 2013 |
$4.81 |
| 2012 |
$3.86 |
| 2011 |
$3.49 |
| 2010 |
$4.78 |
| 2009 |
$4.40 |
| Johnson & Johnson Quarterly EPS |
| 2024-09-30 |
$1.11 |
| 2024-06-30 |
$1.93 |
| 2024-03-31 |
$1.34 |
| 2023-12-31 |
$1.58 |
| 2023-09-30 |
$10.21 |
| 2023-06-30 |
$1.96 |
| 2023-03-31 |
$-0.03 |
| 2022-12-31 |
$1.32 |
| 2022-09-30 |
$1.68 |
| 2022-06-30 |
$1.80 |
| 2022-03-31 |
$1.93 |
| 2021-12-31 |
$1.77 |
| 2021-09-30 |
$1.37 |
| 2021-06-30 |
$2.35 |
| 2021-03-31 |
$2.32 |
| 2020-12-31 |
$0.65 |
| 2020-09-30 |
$1.33 |
| 2020-06-30 |
$1.36 |
| 2020-03-31 |
$2.17 |
| 2019-12-31 |
$1.50 |
| 2019-09-30 |
$0.66 |
| 2019-06-30 |
$2.08 |
| 2019-03-31 |
$1.39 |
| 2018-12-31 |
$1.12 |
| 2018-09-30 |
$1.44 |
| 2018-06-30 |
$1.45 |
| 2018-03-31 |
$1.60 |
| 2017-12-31 |
$-3.91 |
| 2017-09-30 |
$1.37 |
| 2017-06-30 |
$1.40 |
| 2017-03-31 |
$1.61 |
| 2016-12-31 |
$1.38 |
| 2016-09-30 |
$1.53 |
| 2016-06-30 |
$1.43 |
| 2016-03-31 |
$1.59 |
| 2015-12-31 |
$1.14 |
| 2015-09-30 |
$1.20 |
| 2015-06-30 |
$1.61 |
| 2015-03-31 |
$1.53 |
| 2014-12-31 |
$0.89 |
| 2014-09-30 |
$1.66 |
| 2014-06-30 |
$1.51 |
| 2014-03-31 |
$1.64 |
| 2013-12-31 |
$1.22 |
| 2013-09-30 |
$1.04 |
| 2013-06-30 |
$1.33 |
| 2013-03-31 |
$1.22 |
| 2012-12-31 |
$0.90 |
| 2012-09-30 |
$1.05 |
| 2012-06-30 |
$0.50 |
| 2012-03-31 |
$1.41 |
| 2011-12-31 |
$0.09 |
| 2011-09-30 |
$1.15 |
| 2011-06-30 |
$1.00 |
| 2011-03-31 |
$1.25 |
| 2010-12-31 |
$0.70 |
| 2010-09-30 |
$1.23 |
| 2010-06-30 |
$1.23 |
| 2010-03-31 |
$1.62 |
| 2009-12-31 |
$0.79 |
| 2009-09-30 |
$1.20 |
| 2009-06-30 |
$1.15 |
| 2009-03-31 |
$1.26 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$345.687B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
